$RRC

RRC Maintained by UBS -- Price Target Lowered to $44

UBS maintained a Neutral rating for Range Resources (RRC) but lowered its price target from $49 to $44. The company's stock is currently trading at $38.23, with a GF Value™ of $45.98, suggesting it is undervalued by 16.9%. RRC has a GF Score™ of 78/100, indicating strong financial health and valuation metrics. Insider activity shows recent selling, reflecting cautious sentiment.

Original reporting
Published Oct 2, 2026, 7:38 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 2, 2026, 8:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$RRC
Bearish
high confidence
Mentioned
$RRC
Relevance
5/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$RRCBearishMed
01

Why it matters

The UBS downgrade may trigger short‑term selling pressure, but longer‑term fundamentals remain tied to gas price trends.

02

Market read

Analyst target cuts are a common catalyst for price moves; this update provides a modest trading signal for RRC.

03

What to watch

Potential upside from upcoming natural‑gas demand recovery or new contract wins not yet reflected in the rating.

Relevance 5/10Novelty 5/10Timing: today

Background

Range Resources is a mid‑cap natural‑gas producer focused on the Marcellus Shale. The sector has been volatile due to fluctuating commodity prices.

Company-level read

Ticker impact

$RRCBearishHigh confidence
Context

UBS lowered its price target for Range Resources to $44 and kept a Neutral rating, indicating a fresh, bearish outlook.

Expected impact

likely pressure as investors price in the lower target

Evidence & confidence

Analyst target reductions historically precede short-term price declines, especially when no offsetting positive news is present.

Market effects

May weigh on other natural‑gas producers as analysts reassess energy pricing outlook.

Limited to U.S. energy stocks; no broader market effect.

Low; the news is company‑specific.

Counterpoint

If the price target cut reflects overly cautious sentiment, the stock could be undervalued and present a buying opportunity.

Key entities

  • Range Resources

    U.S. natural‑gas and NGL producer (ticker RRC).

  • UBS

    Investment bank that issued the rating update.

Related articles

$RRCMed

Range Announces Second Quarter 2026 Results

RANGE RESOURCES CORP (RRC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 rrc-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 NEWS RELEASE Range Announces Second Quarter 2026 Results FORT WORTH, TEXAS, July 21, 2026…RANGE RESOURCES CORPORATION (NYSE: RRC) today announced its second quarter 2026 financial results. Second Quarter 2026 Highlights – • Ca

$RRCMed

Range Resources (NYSE:RRC) Reports Bullish Q2 CY2026

Range Resources (NYSE:RRC) reported Q2 CY2026 revenue of $833.6 million, up 19.3% year on year and 15.2% above Wall Street estimates, according to the company. Non-GAAP profit was $0.79 per share, 21.5% above consensus. The article also cites Q2 free cash flow of $235 million and a 28.2% margin, with shares down 2.2% to $36.92 after results.

$RRCMed

Why Range Resources (RRC) Stock Is Trading Lower Today

Range Resources (RRC) shares fell about 3.7% to $35.36 after UBS cut its price target to $44 from $49 and Stephens trimmed its target to $52 from $53, citing a weaker natural gas outlook. The changes followed a drop in U.S. natural gas futures to a six-week low on expectations of lower LNG demand and higher-than-expected storage.

$GMABMedAI 8/10

Genmab reports trial results for ovarian cancer drug candidate

Genmab (GMAB) reported Phase 1/2 trial results for rinatabart sesutecan in platinum-resistant ovarian cancer, showing a 45.9% response rate and median progression-free survival of 9.5 months. The trial involved 109 patients, with common side effects including fatigue, nausea, and anemia. The drug is being evaluated in four Phase 3 trials for various gynecologic cancers.